Lipid nanoparticles (LNP) are the only clinically approved non-viral RNA delivery vehicle. Their safety has been demonstrated by the successes of mRNA vaccines after the recent coronavirus outbreak. COVID-19 vaccines rapidly adopted LNPs due to their ease of formulation, protective properties, and large payload capacity. LNPs are now accelerating the development of mRNA therapeutic applications in humans beyond vaccination.
Further developments are still needed to improve biodistribution and stability of mRNA-LNPs while reducing their toxicity. The ionizable cationic lipid within the LNP formulation influences which organs are transfected as well as mRNA delivery efficiency and degradability. Polyplus developed a range of cationic lipids used in LNP formulation named LipidBrick®. These lipids can modulate physicochemical properties and impact subsequent potency and biodistribution of formulated LNPs while improving mRNA stability.
Need certificate of analysis ?
In order to download a product protocol or a certificate of analysis, please create an account on Polyplus®Portal.
Create an account to discover our :
- Certificate of Analysis
- Plasmid Design Platform
- Product Protocols
- All exclusive gated content
Search for publications in the Transfection Database with Polyplus transfection reagents or for transfection conditions.
Over 6000 publications, 1000 cell lines and primary cells available.
You have access to all the documents transfection reagent.
In order to download a product protocol or a certificate of analysis, please create an account on Polyplus
Scientific support specialists
Your needs are too complex to be explained in few words ? Feel free to use our dedicated contact form for a full support !
Do you have a question ?
Feel free to ask your question.Our team answer you quickly !